Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of LY4100511 in Moderate-to-Severe Plaque Psoriasis
jRCT2031240450Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of simepdekinra in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: PASI 75 response at Week 12. Started Nov 2024; status: active, not recruiting.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031240450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240450.